

Appendix C—National Defense Authorization Act, Section 703 Affected Medications

A. Drugs Retained as Formulary on the Uniform Formulary			
Product Name	Subclass	Manufacturer	Number of Affected Patients
TARCEVA	Antineoplastic systemic enzyme inhibitors	GENENTECH, INC.	2068
TARGRETIN	Oral oncological agents	EISAI INC.	49
B. Drugs moved to or retained as nonformulary on the Uniform Formulary			
Product Name	Subclass	Manufacturer	Number of Affected Patients
FLUOROPLEX	Topical antineoplastic & premalignant lesion medic	ALLERGAN INC.	393
PANRETIN	Topical antineoplastic & premalignant lesion medic	EISAI INC.	2
SUBOXONE	Narcotic analgesics & combos	RECKITT BENCKIS	590
SUBUTEX	Narcotic analgesics & combos	RECKITT BENCKIS	80
TAZORAC	Psoriasis medications	ALLERGAN INC.	9690